Appili Therapeutics Announces Results for Resolutions at Annual General Meeting of Shareholders
08 September 2021 - 1:17PM
Business Wire
Capital Markets Veteran Josef Vejvoda to Join
Appili Board of Directors as New Director
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the
“Company” or “Appili”), a biopharmaceutical company focused on drug
development for infectious diseases, today announced the results
from its annual general meeting of shareholders held on Tuesday,
September 7, 2021. The Company also announced the addition of Josef
Vejvoda to its Board of Directors (the “Board”).
Based on the proxies received and the vote conducted at the
meeting, all tabled resolutions were approved by the shareholders
of the Company, including the election of the following directors
for the ensuing year: Ian Mortimer, Brian Bloom, Juergen Froehlich,
Theresa Matkovits, Rochelle Stenzler, Armand Balboni, and newly
elected Josef Vejvoda.
Voting results for each director are summarized below:
Name of Nominee
Percentage of Votes
For
Percentage of Votes
Withheld
Ian Mortimer
99.85%
0.15%
Brian Bloom
100%
0%
Juergen Froehlich
99.85%
0.15%
Theresa Matkovits
99.85%
0.15%
Rochelle Stenzler
100%
0%
Armand Balboni
100%
0%
Josef Vejvoda
100%
0%
Josef Vejvoda brings to Appili’s Board over 25 years of capital
markets experience. Mr. Vejvoda currently acts as special advisor
to K2 & Associates Investment Management Inc. (“K2”), a
multi-strategy investment fund, and previously held senior
operating executive positions at K2 as Chief Compliance Officer and
Chief Executive Officer. Mr. Vejvoda has also held senior
management roles at a number of the country’s largest financial
institutions, including Merrill Lynch Canada, National Bank
Financial, and TD Securities, as well as serving on numerous public
company boards.
Mr. Vejvoda graduated from Queen’s University with a BSc in
Computer Science. Mr. Vejvoda has also earned the Chartered
Investment Manager (CIM®) designation from the Canadian Securities
Institute and is a graduate of the Institute of Corporate Directors
having achieved the ICD.D designation.
Shareholders also approved the re-appointment of
PricewaterhouseCoopers, LLP, Chartered Accountants, as independent
auditor of the Company for the ensuing year and authorized the
directors of the Company to fix their remuneration.
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical
company that is purposefully built, portfolio-driven, and
people-focused to fulfill its mission of solving life-threatening
infections. By systematically identifying urgent infections with
unmet needs, Appili’s goal is to strategically develop a pipeline
of novel therapies to prevent deaths and improve lives. As part of
a global consortium, Appili is sponsoring late-stage clinical
trials evaluating the antiviral Avigan/Reeqonus for the worldwide
treatment and prevention of COVID-19. The Company is also advancing
a diverse range of anti-infectives, including a broad-spectrum
antifungal, a vaccine candidate to eliminate a serious biological
weapon threat, and two novel antibiotic programs. Led by a proven
management team, Appili is at the epicenter of the global fight
against infection. For more information, visit
www.AppiliTherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210908005350/en/
Media Contacts Danielle Raabe/APCO Worldwide T:
1-646-717-9915 Email: DRaabe@apcoworldwide.com
Investor Relations Contacts Kimberly Stephens, CFO Appili
Therapeutics E: Info@AppiliTherapeutics.com
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
Von Apr 2023 bis Apr 2024